natgillin/translations-raw huggingface dataset:
Der er publicerede tilfælde af bronkiektasi hos voksne og børn, der har fået Mycophenolatmofetil i kombination med andre immunsuppressiva. 
There have been published reports of bronchiectasis in adults and children who received mycophenolate mofetil in combination with other immunosuppressants.
• misdannelser i nervesystemet såsom rygmarvsbrok; 
• Nervous system malformations such as spina bifida;
• hvis du ikke anvender effektiv prævention (se ”Graviditet, prævention og amning”) 
• If you are pregnant or planning to become pregnant or think you may be pregnant If you are not using effective contraception (see Pregnancy, contraception and breast-feeding).
Patienter, der får immunosuppressiv behandling med kombinationer af lægemidler, inklusive mycophenolatmofetil, har forøget risiko for at udvikle lymfomer og andre maligne lidelser, især i huden (se pkt. 
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4).
Gelatine, titandioxid (E 171) 
Titanium dioxide (E 171)
Den i dyre carcinogenicitetsundersøgelser højest testede dosis resulterede i ca. 2 - 3 gange den systemiske eksponering (AUC eller Cmax), der er observeret hos nyretransplanterede patienter, der fik den anbefalede kliniske dosis på 2 g daglig og 1,3 - 2 gange den systemiske eksponering (AUC eller Cmax) observeret hos hjertetransplanterede patienter, der fik den anbefalede kliniske dosis på 3 g daglig. 
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2-3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3-2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day.
• Tag 6 kapsler om morgenen og 6 kapsler om aftenen. 
• Take 6 capsules in the morning and then 6 capsules in the evening.
Sådan et blodbillede kan fejlagtigt blive tolket som et tegn på infektion hos immunsupprimerede patienter, som dem der behandles med mycophenolatmofetil. 
These changes may suggest a ‘left shift' in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.
• hvis du ammer. 
If you are breast-feeding.
Opkastning, abdominalsmerter, diarré, kvalme Almindelig Gastrointestinal blødning, peritonitis, ileus, colitis, mavesår, ulcus duodeni, gastritis, oesophagitis, stomatitis, obstipation, dyspepsi, flatulens, opstød 
Common Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation
Farmakokinetikken af orale kontraceptiva påvirkedes ikke af samtidig administration af mycophenolatmofetil (se også pkt. 
The pharmacokinetics of oral contraceptives were unaffected by coadministration of mycophenolate mofetil (see also section 4.5).
I kontrollerede kliniske studier hos nyre- (2 g data), hjerte- og levertransplanterede patienter, som blev fulgt i mindst 1 år, var de almindeligste opportunistiske infektioner hos patienter, som fik mycophenolatmofetil (2 g eller 3 g daglig) sammen med andre immunsupprimerende stoffer, mukokutane candidainfektioner, CMV-viræmi/syndrom og herpes simplex-infektioner. 
The most common opportunistic infections in patients receiving mycophenolate mofetil (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex.
Anvendelse i forbindelse med nyretransplantation 
Use in renal transplant
Patienter, der får immunosuppressiv behandling med kombinationer af lægemidler, som inkluderer Myclausen, har forøget risiko for at udvikle lymfomer og andre maligne lidelser, især i huden (se pkt. 
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myclausen, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
6.1 Der er observeret overfølsomhedsreaktioner over for Myclausen (se pkt. 
Hypersensitivity reactions to mycophenolate mofetil have been observed (see section 4.8).
Baseret på resultaterne fra en undersøgelse med enkelt dosis indgift af anbefalede doser af oral mycophenolatmofetil og i.v.. ganciclovir og de kendte virkninger af nedsat nyrefunktion på mycophenolatmofetils og ganciclovirs farmakokinetik (se pkt. 
Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration.
Før Myclausen-behandlingen initieres, skal fertile kvinder have to negative graviditetstests (serum eller urin) med en sensitivitet på mindst 25 mIE/ml for at udelukke en uønsket mycophenolateksponering til fosteret.Det anbefales, at test nummer 2 skal udføres 8-10 dage efter den første test. Ved modtagelse af transplantater fra afdøde donorer, kan det på grund af tidspunktet for tilgængeligheden af transplantationsorganet, ikke altid være muligt at udføre to tests 8-10 dage efter hinanden, inden behandlingen initieres. 
It is recommended that the second test should be performed 8 - 10 days after the first test. For transplants from deceased donors, if it is not possible to perform two test 8 - 10 days apart before treatment starts (because of the timing of transplant organ availability), a pregnancy test must be performed immediately before starting treatment and a further test performed 8 - 10 days later.
• Myclausen må ikke anvendes til ammende kvinder (se pkt. 
• Myclausen should not be given to women who are breastfeeding (see section 4.6).
• Myclausen må ikke anvendes til patienter med overfølsomhed over for mycophenolatmofetil, mycophenolsyre eller et eller flere af hjælpestofferne anført i pkt. 
• Myclausen should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1.
• rysten, muskelkramper, kramper 
• tremor, muscle spasms, convulsions
Meget almindelig Almindelig Agitation, konfusion, depression, angst, abnorm tankevirksomhed, insomnia 
anxiety, thinking abnormal, insomnia
Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om. 
You should check with your doctor or pharmacist if you are not sure.
Lægemidlet må kun udleveres efter begrænset recept (jf. bilag I: Produktresumé; pkt. 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
• Tag 4 kapsler om morgenen og 4 kapsler om aftenen. 
• Take 4 capsules in the morning then 4 capsules in the evening.
Myclausen måske afbrydes eller stoppes. 
3/µl), it may be appropriate to interrupt or discontinue Myclausen.
Levertransplantation 
Liver transplant
Der findes ingen tilgængelige data for hjerte- eller levertransplanterede patienter med svær, kronisk nedsat nyrefunktion. 
No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.
Den anbefalede dosis til nyretransplanterede patienter er 1 g administreret to gange daglig (daglig dosis: 2 g). 
The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose).
Der er rapporteret hypogammaglobulinæmi i forbindelse med tilbagevendende infektioner hos patienter, der har fået Mycophenolatmofetil i kombination med andre immunsuppressiva. 
There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving mycophenolate mofetil in combination with other immunosuppressants.
Andre uønskede hændelser 
Other adverse reactions
Der blev ikke set signifikante forskelle i hyppigheden af afstødning eller tab af transplantat hos mycophenolatmofetil-patienter, som tog protonpumpehæmmer versus mycophenolatmofetil-patienter, som ikke tog protonpumpehæmmer. 
When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs versus mycophenolate mofetil patients not taking PPIs, no significant differences were seen.
Brug af anden medicin sammen med Myclausen Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Forsinket renal transplantatfunktion 
Delayed renal graft function
• Du får tidligst den første dosis Myclausen til indtagelse gennem munden 4 dage efter transplantationen. 
• The first dose of oral Myclausen will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medications.
4.3), inden behandling med Myclausen påbegyndes, under behandlingen og i seks uger efter behandlingsophør, medmindre seksuel afholdenhed er den valgte form for prævention. 
Therefore women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Myclausen therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception.
MPA og MPAG i kliniske koncentrationer fjernes ikke ved hæmodialyse. 
At clinically encountered concentrations, MPA and MPAG are not removed by haemodialysis.
Colestyramin 
Cholestyramine
LÆGEMIDLETS NAVN Myclausen 250 mg hårde kapsler Mycophenolatmofetil 
NAME OF THE MEDICINAL PRODUCT Myclausen 250 mg hard capsules Mycophenolate mofetil
Kapselindhold prægelatineret stivelse (majs) croscarmellosenatrium povidon (K-30) magnesiumstearat 
Capsule content Pregelatinised starch (maize) Croscarmellose sodium Povidone (K-30) Magnesium stearate
I en undersøgelse af fertilitet og reproduktion udført på hunrotter forårsagede orale doser på 4,5 mg/kg/dag misdannelser (inkl. 
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
Tablet-kerne mikrokrystallinsk cellulose povidon (K-30) croscarmellosenatrium magnesiumstearat 
Microcrystalline cellulose Povidone (K-30) Croscarmellose sodium Magnesium stearate
Ydermere, at mænd ikke må være sæddonorer under behandlingen og i 90 dage efter, at mycophenolat er seponeret. 
Furthermore, men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.
ved fordøjelsesbesvær) 
It may harm them,
• I 6 uger efter du er stoppet med at tage Myclausen. 
This includes: Before you start taking Myclausen During your entire treatment with Myclausen For 6 weeks after you stop taking Myclausen.
Myclausen 500 mg filmovertrukne tabletter Mycophenolatmofetil 
Myclausen 500 mg film-coated tablets Mycophenolate mofetil
LÆGEMIDLETS NAVN Myclausen 500 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT Myclausen 500 mg film-coated tablets
Tilfælde af BK-virus associeret med nefropati såvel som tilfælde af JC-virus associeret med progressiv multifokal leukoencefalopati (PML) er blevet rapporteret hos patienter, der behandles med immunosuppressiva herunder mycophenolatmofetil. 
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including mycophenolate mofetil. Agranulocytosis (≥ 1/1000 to < 1/100) and neutropenia have been reported; therefore, regular monitoring of patients taking Myclausen is advised (see section 4.4).
Der blev ikke set kliniske konsekvenser af de farmakokinetiske lægemiddelinteraktioner ved sammenligning af hyppigheden af afstødning af transplantat eller tab af transplantat eller bivirkningsprofilen mellem mycophenolatmofetil-patienter med og uden samtidig telmisartan-medicinering. 
When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between mycophenolate mofetil patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic medicinal product-medicinal product interaction were seen.
Den systemiske eksponering på disse niveauer er omtrent lig med eller mindre end 0,5 gange den kliniske eksponering ved den anbefalede dosis på 2 g daglig til nyretransplanterede patienter og ca. 0,3 gange den kliniske eksponering ved den anbefalede kliniske dosis på 3 g daglig til hjertetransplanterede patienter (se pkt. 
The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients (see section 4.6).
Den systemiske eksponering af denne dosis repræsenterer 2-3 gange den kliniske eksponering ved den anbefalede kliniske dosis på 2 g daglig til nyretransplanterede patienter og 1,3 - 2 gange den kliniske eksponering ved den anbefalede kliniske dosis på 3 g daglig til hjertetransplanterede patienter. 
The systemic exposure at this dose represents 2-3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3-2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients.
Hudlidelser såsom: • akne, forkølelsessår, helvedesild (herpes zoster), øget hudvækst, hårtab, udslæt, kløe. 
Skin problems such as: • acne, cold sores, shingles, skin growth, hair loss, rash, itching.
Nyretransplantation 
Kidney transplant
Antacida og protonpumpehæmmere 
Antacids and proton pump inhibitors (PPIs)
Myclausen 250 mg håde kapsler Mycophenolatmofetil 
Myclausen 250 mg hard capsules Mycophenolate mofetil
Den anbefalede dosis til hjertetransplanterede patienter er 1,5 g administreret to gange daglig (daglig dosis: 3 g). 
The recommended dose in cardiac transplant patients is 1.5 g administered twice daily (3 g daily dose).
Efter markedsføring er der blevet observeret medfødte misdannelser hos børn af patienter, der har været eksponeret for Myclausen i kombination med andre immunsuppressiva, se pkt. 
Congenital malformations have been observed post-marketing in children of patients exposed to mycophenolate mofetil in combination with other immunosuppressants, see section 4.6.
Mikrokrystallinsk cellulose, povidon (K-30), croscarmellosenatrium, magnesiumstearat 
Tablet core: Microcrystalline cellulose, povidone (K-30), croscarmellose sodium, magnesium stearate
Aktivt stof: mycophenolatmofetil Hver tablet indeholder 500 mg mycophenolatmofetil Øvrige indholdsstoffer: 
The active substance is mycophenolate mofetil. Each tablet contains 500 mg mycophenolate mofetil
Den systemiske eksponering af denne dosis var ca. 0,5 gange den kliniske eksponering af den anbefalede kliniske dosis på 2 g daglig til nyretransplanterede patienter og ca. 0,3 gange den kliniske eksponering ved den anbefalede kliniske dosis på 3 g daglig til hjertetransplanterede patienter. 
The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/10/647/001-002 
MARKETING AUTHORISATION NUMBER(S) EU/1/10/647/001-002
LÆGEMIDDELFORM Filmovertrukken tablet. 
PHARMACEUTICAL FORM Film-coated tablet White round film-coated tablets.
Indehaveren af markedføringstilladelsen vil sikre uddannelsesmateriale til sundhedspersonale, for at hjælpe patienter med at undgå føtal eksponering af mycophenolat og for at fremskaffe yderligere vigtig sikkerhedsinformation. 
In order to assist patients in avoiding foetal exposure to mycophenolate and to provide additional important safety information, the Marketing Authorisation holder will provide educational materials to healthcare professionals.
LÆGEMIDLETS NAVN Myclausen 500 mg filmovertrukne tabletter Mycophenolatmofetil 
NAME OF THE MEDICINAL PRODUCT Myclausen 500 mg film-coated tablets Mycophenolate mofetil
- Lægen har ordineret Myclausen til dig personligt. 
- This medicine has been prescribed for you only.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 500 mg mycophenolatmofetil. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 500 mg mycophenolate mofetil.
• Den daglige dosis er 8 kapsler (2 g af medicinen) indtaget som 2 separate doser. 
• The daily dose is 8 capsules (2 g of the medicine) taken as 2 separate doses.
I nogle af disse tilfælde sås forbedringer i de respiratoriske symptomer, når Mycophenolatmofetil blev erstattet af alternative immunsuppressiva. 
In some of these cases switching mycophenolate mofetil to another immunosuppressant resulted in improvement in respiratory symptoms.
Sådan skal du tage Myclausen 
How to take Myclausen
Indtagelse af Myclausen 
How to store Myclausen
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 250 mg mycophenolatmofetil. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 250 mg mycophenolate mofetil.
Fortsæt dog behandlingen, indtil du ser lægen. 
However, keep taking Myclausen until you see him or her.
Undgå inhalation og undgå at hud og slimhinder kommer i direkte kontakt med pulveret i Myclausen kapslerne. 
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Myclausen capsules should not be opened or crushed to avoid inhalation or direct contact with skin or mucous membranes of the powder contained in Myclausen capsules.
Undgå pulver fra itugåede kapsler kommer i kontakt med dine øjne eller mund. 
Take care not to let any powder from inside a broken capsule get into your eyes or mouth • If this happens, rinse with plenty of water.
Pædiatrisk population Der er ingen tilgængelige data vedrørende hjertetransplantationer hos pædiatriske patienter. 
No data are available for paediatric cardiac transplant patients.
• Den daglige dosis er 4 tabletter (2 g af medicinen) indtaget som 2 separate doser. 
• The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.
Mænd må ikke være sæddonorer under behandlingen og i mindst 90 dage efter seponering af mycophenolat. 
Men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.
Den anbefalede orale Myclausen dosis til levertransplanterede patienter er 1,5 g to gange daglig (daglig dosis: 3 g). 
The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose).
I kontrollerede kliniske studier hos nyre- (2 g data), hjerte- og levertransplanterede patienter, som kontrolleredes i mindst 1 år, udvikledes lymfoproliferativ sygdom eller lymfomer hos 0,6 % af de patienter som fik mycophenolatmofetil (2 eller 3 g daglig) sammen med andre immunsuppressive stoffer. 
Lymphoproliferative disease or lymphoma developed in 0.6 % of patients receiving mycophenolate mofetil (2 g or 3 g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year.
Hvis du er kvinde og kan blive gravid, skal du bruge en effektiv præventionsmetode, mens du tager Myclausen, herunder: 
Contraception in women taking Myclausen If you are a woman who could become pregnant you must use an effective methods of contraception with Myclausen.
Der er rapporteret om enkelte tilfælde af interstitiel lungesygdom og lungefibrose hos patienter, som fik mycophenolatmofetil i kombination med andre immunosuppressiva. 
There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with mycophenolate mofetil in combination with other immunosuppressants, some of which have been fatal.
I nogle af disse tilfælde blev serum-IgG normaliseret, når Mycophenolatmofetil blev erstattet af alternative immunsuppressiva. 
In some of these cases switching mycophenolate mofetil to an alternative immunosuppressant resulted in serum IgG levels returning to normal.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukket tablet indeholder 500 mg mycophenolatmofetil. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg mycophenolate mofetil. For the full list of excipients, see section 6.1.
Informationsmaterialet for patienter skal indeholde: · Indlægsseddel · En vejledning for patienter 
· The Package Leaflet · Guide for patients
• Den daglige dosis er 6 tabletter (3 g af medicinen) indtaget som 2 separate doser. 
• The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/10/647/001 
MARKETING AUTHORISATION NUMBER(S) EU/1/10/647/001
Hvis du vil have yderligere oplysninger om Myclausen, skal du henvende dig til den lokale repræsentant: 
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/10/647/002 
MARKETING AUTHORISATION NUMBER(S) EU/1/10/647/002
6 Pakningsstørrelser og yderligere oplysninger 
5 How to store Myclausen 6 Contents of the pack and other information
• Den daglige dosis er 12 kapsler (3 g af medicinen) indtaget som 2 separate doser. 
• The daily dose is 12 capsules (3 g of the medicine) taken as 2 separate doses.
Prægelatineret stivelse (majs), croscarmellosesodium, povidon (K-30), magnesiumstearat Kapselskallen: 
Capsule content: pre-gelatinised starch (maize), croscarmellose sodium, povidone (K-30), magnesium stearate
Lidelser i mave-tarm-kanalen og i munden såsom: 
Digestive system and mouth problems such as:
Oversigt over indlægssedlen: 
The patient information pack should contain:
Der findes ingen tilgængelige data for hjertetransplanterede patienter med svær leverparenkymsygdom. 
No data are available for cardiac transplant patients with severe hepatic parenchymal disease.
anophthalmi, agnathi og hydrocephalus) og hos kaniner ved 90 mg/kg/dag (inkl. 
In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity.
• hævede gummer og sår i mundhulen 
• swelling of the gums and mouth ulcers
Mavetarmkanalen 
Common Arthralgia
Lægen skal give fertile kvinder og mænd udførlig information om de teratogene risici og forholdsregler til at forebygge graviditet. 
Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients.
AUC0-12 timer med henholdsvis 30 % og 25 %, dog uden at dette havde kliniske konsekvenser (f.eks. 
Decrease in MPA Cmax and AUC (0-12h) by 30 % and 25 %, respectively, were observed when mycophenolate mofetil was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection).
Oral mycophenolatmofetils gennemsnitlige biotilgængelighed, baseret på MPA-AUC, er 94 % i forhold til i.v. 
The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94 % relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients.
Ciclosporin 
Ciclosporin A
Hvis du har taget for mange Myclausen 
If you take more Myclausen than you should
Bivirkninger Almindelig Pleural effusion, dyspnø, hoste 
Vomiting, abdominal pain, diarrhoea, nausea